Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
MRNA's Cash to Debt is ranked higher than
99% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: 56.38 vs. MRNA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MRNA' s Cash to Debt Range Over the Past 10 Years
Min: 0.05  Med: 247.36 Max: No Debt
Current: No Debt
Equity to Asset 0.21
MRNA's Equity to Asset is ranked lower than
88% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. MRNA: 0.21 )
Ranked among companies with meaningful Equity to Asset only.
MRNA' s Equity to Asset Range Over the Past 10 Years
Min: -2  Med: 0.63 Max: 0.95
Current: 0.21
-2
0.95
F-Score: 5
Z-Score: -63.03
M-Score: -4.86
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -395.16
MRNA's Operating margin (%) is ranked lower than
69% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. MRNA: -395.16 )
Ranked among companies with meaningful Operating margin (%) only.
MRNA' s Operating margin (%) Range Over the Past 10 Years
Min: -2259.18  Med: -443.64 Max: -17.26
Current: -395.16
-2259.18
-17.26
Net-margin (%) 429.03
MRNA's Net-margin (%) is ranked higher than
99% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: -75.29 vs. MRNA: 429.03 )
Ranked among companies with meaningful Net-margin (%) only.
MRNA' s Net-margin (%) Range Over the Past 10 Years
Min: -2269.84  Med: -257.57 Max: 490.74
Current: 429.03
-2269.84
490.74
ROA (%) 51.82
MRNA's ROA (%) is ranked higher than
99% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: -27.73 vs. MRNA: 51.82 )
Ranked among companies with meaningful ROA (%) only.
MRNA' s ROA (%) Range Over the Past 10 Years
Min: -158.44  Med: -78.17 Max: 39.7
Current: 51.82
-158.44
39.7
Revenue Growth (3Y)(%) -59.40
MRNA's Revenue Growth (3Y)(%) is ranked lower than
87% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.40 vs. MRNA: -59.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MRNA' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -72.9  Med: -33.60 Max: 72
Current: -59.4
-72.9
72
EPS Growth (3Y)(%) -41.80
MRNA's EPS Growth (3Y)(%) is ranked lower than
99.99% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. MRNA: -41.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MRNA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -82.1  Med: -21.75 Max: 101
Current: -41.8
-82.1
101
» MRNA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with MRNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:KNBIF, OTCPK:APTCF, NAS:STEM, OTCPK:TIKRF, OTCPK:SVON, OTCPK:HADSY, OTCPK:AMBS, OTCPK:VRTHF, OTCPK:REPCF, OTCPK:ICOTF, OTCPK:CNBX, OTCPK:BLVKF, NAS:LPTN, OTCPK:MDFZF, OTCPK:RGIN, NAS:GBIM, OTCPK:VXLLF, OTCPK:PCNT, OTCPK:VDQSF, OTCPK:GOVX » details
Marina Biotech Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases.

Marina Biotech, Inc., formerly known as Nastech Pharmaceutical Company Inc., was incorporated in Delaware in 1983. The Company is a biotechnology company focused on the discovery, development and commercialization of nucleic acid-based therapies utilizing gene silencing approaches such as RNA interference ('RNAi') and blocking messenger RNA ('mRNA') translation. It has multiple proprietary technologies integrated into a nucleic acid-based drug discovery platform, with the capability to deliver novel nucleic acid-based therapeutics via systemic, local and oral administration to target a range of human diseases, based on the unique characteristics of the cells and organs involved in each disease. Its pipeline includes a clinical program in Familial Adenomatous Polyposis ('FAP') and preclinical programs in bladder cancer and myotonic dystrophy. In addition to its own, internally developed technologies, it has strategically in-licensed and further developed nucleic acid- and delivery-related technologies, forming an integrated drug discovery platform. It is employing its platform, through its own efforts and those of its partners, for the discovery of multiple nucleic acid-based therapeutics including siRNA, microRNA, and single stranded oligonucleotide-based drugs. It's competitors include Alnylam Pharmaceuticals, Benitec Biopharma, Dicerna Pharmaceuticals, miRagen Therapeutics, Mirna Therapeutics, Quark Pharmaceuticals, Regulus Therapeutics, Silence Therapeutics, and Tekmira Pharmaceuticals. The Company is subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specific waste products. It is also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of bio-hazardous materials.

Ratios

vs
industry
vs
history
Price/Owner Earnings (ttm) 0.48
MRNA's Price/Owner Earnings (ttm) is ranked higher than
99% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 34.05 vs. MRNA: 0.48 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MRNA' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 0.93  Med: 4.25 Max: 9.7
Current: 0.48
0.93
9.7
P/B 2.75
MRNA's P/B is ranked higher than
50% of the 1024 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. MRNA: 2.75 )
Ranked among companies with meaningful P/B only.
MRNA' s P/B Range Over the Past 10 Years
Min: 0.45  Med: 4.36 Max: 387.5
Current: 2.75
0.45
387.5
P/S 3.59
MRNA's P/S is ranked higher than
75% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 12.56 vs. MRNA: 3.59 )
Ranked among companies with meaningful P/S only.
MRNA' s P/S Range Over the Past 10 Years
Min: 0.49  Med: 5.36 Max: 70.12
Current: 3.59
0.49
70.12
EV-to-EBIT 1.97
MRNA's EV-to-EBIT is ranked higher than
81% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 22.27 vs. MRNA: 1.97 )
Ranked among companies with meaningful EV-to-EBIT only.
MRNA' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.9  Med: -1.20 Max: 15.3
Current: 1.97
-13.9
15.3
EV-to-EBITDA 1.97
MRNA's EV-to-EBITDA is ranked higher than
83% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 18.12 vs. MRNA: 1.97 )
Ranked among companies with meaningful EV-to-EBITDA only.
MRNA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.6  Med: -1.30 Max: 15.3
Current: 1.97
-14.6
15.3
Current Ratio 0.15
MRNA's Current Ratio is ranked lower than
98% of the 903 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. MRNA: 0.15 )
Ranked among companies with meaningful Current Ratio only.
MRNA' s Current Ratio Range Over the Past 10 Years
Min: 0.03  Med: 2.53 Max: 21.21
Current: 0.15
0.03
21.21
Quick Ratio 0.15
MRNA's Quick Ratio is ranked lower than
97% of the 903 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. MRNA: 0.15 )
Ranked among companies with meaningful Quick Ratio only.
MRNA' s Quick Ratio Range Over the Past 10 Years
Min: 0.03  Med: 2.50 Max: 21.07
Current: 0.15
0.03
21.07

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.67
MRNA's Price/Median PS Value is ranked higher than
62% of the 734 Companies
in the Global Biotechnology industry.

( Industry Median: 0.94 vs. MRNA: 0.67 )
Ranked among companies with meaningful Price/Median PS Value only.
MRNA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.11  Med: 1.65 Max: 22.95
Current: 0.67
0.11
22.95
Earnings Yield (Greenblatt) (%) 50.80
MRNA's Earnings Yield (Greenblatt) (%) is ranked higher than
95% of the 1104 Companies
in the Global Biotechnology industry.

( Industry Median: -9.68 vs. MRNA: 50.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MRNA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 6.5  Med: 66.55 Max: 132.5
Current: 50.8
6.5
132.5

More Statistics

Revenue (TTM) (Mil) $0.93
EPS (TTM) $ -0.16
Beta0.79
Short Percentage of Float8.22%
52-Week Range $0.11 - 0.52
Shares Outstanding (Mil)29.76
» More Articles for MRNA

Headlines

Articles On GuruFocus.com
MDRNA Inc. Reports Operating Results (10-Q) Nov 15 2010 
MDRNA Inc. Reports Operating Results (10-Q) May 17 2010 
MDRNA Inc. Reports Operating Results (10-Q) Nov 12 2009 
MDRNA Inc. Reports Operating Results (10-Q) Jul 30 2009 
MDRNA Inc. Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
MARINA BIOTECH, INC. Files SEC form 8-K, Other Events Jun 24 2016
MARINA BIOTECH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered... Jun 22 2016
MARINA BIOTECH, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jun 02 2016
Marina Biotech Announces Resignation of Chairman, President and Chief Executive Officer J. Michael... Jun 02 2016
MARINA BIOTECH, INC. Financials May 21 2016
MARINA BIOTECH, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 17 2016
Marina Biotech Provides First Quarter 2016 Financial Reports and Business Update May 17 2016
MARINA BIOTECH, INC. Files SEC form 10-Q, Quarterly Report May 16 2016
MARINA BIOTECH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 04 2016
Marina Biotech to Acquire Late-Stage Program From Turing Pharmaceuticals May 03 2016
Marina Biotech Terminates Negotiations for Sale of Its Nucleic Acid Therapeutic Assets May 03 2016
MARINA BIOTECH, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Mar 31 2016
Marina Biotech Provides 2015 Year-End Financials and Update Mar 31 2016
MARINA BIOTECH, INC. Files SEC form 10-K, Annual Report Mar 30 2016
MARINA BIOTECH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 16 2016
Marina Biotech Announces a License Agreement to Deliver a Genome Editing Technology Mar 16 2016
Microlin Bio to Acquire Nucleic Acid Therapeutic Assets of Marina Biotech Mar 15 2016
MARINA BIOTECH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 19 2016
Marina Biotech Announces Evaluation and Option Agreement to Deliver a Genome Editing Technology Feb 18 2016
Marina Biotech to Explore Strategic Alternatives Feb 17 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)